medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2015, Number 616

<< Back Next >>

Rev Med Cos Cen 2015; 72 (616)

Carcinoma nasofaríngeo en pediatría

Gamboa CAY, Rodríguez RC, Zúñiga OA

Language: Spanish
References: 25
Page: 627-635
PDF size: 207.22 Kb.


ABSTRACT

Nasopharyngeal carcinoma is a rare disease in children, been more common in the nasopharynx other tumors like lymphomas and rhabdomyosarcomas. This disease has an increased incidence in some endemic areas with specific racial characteristics and it also shows an association with several environmental and genetic factors, such as Epstein- Barr virus. The treatment in these patients is based on a combined therapy composed by chemotherapy and radiotherapy. Many children are diagnosed in advanced stages of the disease; this complicates their therapeutic management, due to the fact that they may present important secondary effects. Patients diagnosed with nasopharyngeal carcinoma, require an integral management provided by different disciplines of the health system, due to the high complexity of this disease. For the follow up of this patients, it has to be considered that most of relapses present within the first two years from diagnose, showing that the relapse pattern is mainly metastatic disease.


REFERENCES

  1. Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003; 4 (1): 13-21.

  2. Brady LW, Heilmann, HP, Molls M, Nieder C. Nasopharyngeal Cancer Multidisciplinary Management. Berlin: Springer; 2010.

  3. Brennan B. Nasopharyngeal Carcinoma. Orphanet Journal of Rare Disease [Internet]. 2006 [consulta el 23 de noviembre de 2014]; 1 (23). Disponible en: http://www.ojrd.com/ content/1/1/23

  4. Casanova M, Bisogno G, Gandola L, Cechetto G, Di Cataldo A, Basso E, et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project. Cancer. 2012; 118 (10): 2718-25.

  5. Clifford K, Perez C, Brady L. Radiation Oncology Management Decisions. 3rd Edition. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2011.

  6. Corchs E, Boschi J. Carcinoma nasofaríngeo en la edad pediátrica. Revisión bibliográfica a propósito de un caso clínico. Rev Chil Radiol. 2007; 13 (2): 63-9.

  7. Coscarón E, Martín EP. Carcinoma epidermoide de nasofaringe. Actualización. [Internet]. 2011 [consulta el 30 de noviembre de 2014]. Disponible en http://www.jano.es/ficheros/ sumarios/1/0/1767/45/00450 053_ LR.pdf

  8. Cox JD, Kian K. Radiation Oncology. 9th Edition. Philadelphia: Mosby Elsevier; 2007.

  9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th Edition. New York: Springer; 2010.

  10. Gunderson L. Clinical Radiation Oncology. 3rd Edition. Philadelphia: Elsevier; 2012.

  11. Halperin EC, Constine LS, Tarbell NJ, Kun LE. Pediatric Radiation Oncology. 5th Edition. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2011.

  12. Halperin EC, Pérez CA, Brady LW. Principles and Practice of Radiation Oncology. 5th Edition. Philadelphia: Lippincott Williams and Wilkins; 2008.

  13. Hansen E, Roach M. Handbook of Evidence Based Radiation Oncology. 2 nd New York: Springer; 2010.

  14. Hu S, Xu X, Xu J, Xu Q, Liu S. Prognostic factors and longterm outcomes of nasopharyngeal carcinoma in children and adolescents. Pediatr Blood Cancer. 2013; 60 (1): 1122-27.

  15. Jalbout M, Bel Hadj Jrad B, Bouaouina N, Gargouri J, Yacoub S, Zakhama A, et al. Autoantibodies to tubulin are specifically associated with the young age onset of the nasopharyngeal carcinoma. Int J Cancer. 2002; 101 (2): 146-50.

  16. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. [Internet]. 2014 [consulta el 29 de diciembre de 2014]. Disponible en https://nccn. org/professionals/physician_gls/f_ guidelines.asp#site

  17. Nieto B, Fernández D, Muriel N, Murga V, García G, Gimeno A. Carcinoma nasofaríngeo en la adolescencia. An Pediatr. 2007; 62 (2): 206-25.

  18. Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. 6th Edition. Philadelphia: Lippincott Williams and Wilkins; 2011.

  19. Rodríguez-Galindo C, et al. Radiation therapy, amifostine, and chemotherapy in treating young patients with newly diagnosed nasopharyngeal cancer. [Internet]. 2014 [consulta el 16 de diciembre de 2014]. Disponible en https:// clinicaltrials.gov/ct2/show/record/ NCT002 74937

  20. Rouge ME, Brisse H, Helfre S, Teissier N, Freneaux P, Orbach D. Le carcinome indifférencié du nasopharynx de l’enfant et de l’adolescent. Bull Cancer. 2011; 98 (3): 337-45.

  21. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, et al. Nasopharyngeal carcinomas: an update. Eur J Cancer. 2003; 39 (1): 2121-35.

  22. Sultan I, Casanova M, Ferrari A, Rihani R, Rodríguez C. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr Blood Cancer. 2010; 55 (2): 279-84.

  23. Universidad de la República. Pautas de Oncología Médica para el diagnóstico, tratamiento sistémico y seguimiento. Montevideo: Universidad de la República; 2012.

  24. Venkatramani R, Mascarenhas L. Successful treatment of recurrent metastatic Nasopharyngeal Carcinoma with oxiliplatin and doxorubicin. J Pediatr Hematol Oncol. 2014; 36 (5): 307-9.

  25. Young LS, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol. 1988; 69 (1): 1051-65.




2020     |     www.medigraphic.com